Point72 Asset Management L.P. purchased a new stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK) during the third quarter, HoldingsChannel.com reports. The firm purchased 267,562 shares of the company’s stock, valued at approximately $4,602,000.
Several other institutional investors have also bought and sold shares of TAK. Prestige Wealth Management Group LLC purchased a new position in Takeda Pharmaceutical in the second quarter worth $25,000. Parallel Advisors LLC lifted its holdings in Takeda Pharmaceutical by 276.3% in the third quarter. Parallel Advisors LLC now owns 1,509 shares of the company’s stock valued at $26,000 after acquiring an additional 1,108 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in Takeda Pharmaceutical in the second quarter valued at $31,000. Coastal Investment Advisors Inc. boosted its position in shares of Takeda Pharmaceutical by 59.8% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock worth $32,000 after purchasing an additional 643 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Takeda Pharmaceutical by 4,645.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,898 shares of the company’s stock worth $34,000 after purchasing an additional 1,858 shares in the last quarter. Hedge funds and other institutional investors own 4.58% of the company’s stock.
A number of brokerages have recently issued reports on TAK. Jefferies Financial Group initiated coverage on shares of Takeda Pharmaceutical in a report on Tuesday, September 24th. They issued a “buy” rating for the company. Daiwa Capital Markets downgraded shares of Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a report on Thursday, August 15th. Zacks Investment Research upgraded shares of Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. Cowen initiated coverage on shares of Takeda Pharmaceutical in a report on Friday, November 1st. They issued a “market perform” rating and a $19.50 target price for the company. Finally, ValuEngine downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $19.25.
Shares of TAK stock opened at $20.56 on Tuesday. The stock has a fifty day moving average price of $19.09 and a 200 day moving average price of $17.76. The stock has a market cap of $63.28 billion, a PE ratio of 40.31 and a beta of 0.76. Takeda Pharmaceutical Co Ltd has a 1 year low of $15.50 and a 1 year high of $21.61. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.94 and a current ratio of 1.45.
Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, October 31st. The company reported $0.59 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 12.52% and a net margin of 3.66%. The company had revenue of $7.56 billion for the quarter. As a group, equities research analysts predict that Takeda Pharmaceutical Co Ltd will post 1.99 earnings per share for the current year.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Article: How mutual funds make money
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.